Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Vismodegib (GDC-0449)

For research use only.

Catalog No.S1082

140 publications

Vismodegib (GDC-0449) Chemical Structure

CAS No. 879085-55-9

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 144 In stock
USD 90 In stock
USD 170 In stock
USD 370 In stock
USD 627 In stock
USD 1070 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vismodegib (GDC-0449) has been cited by 140 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
Targets
Hedgehog [1]
(Cell-free assay)
3 nM
In vitro

GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. GDC-0449 prevents multiple ATP-binding cassette (ABC) transporters. GDC-0449 also blocks ABCG2, Pgp, and MRP1-important ABC transporters associated with MDR. GDC-0449 is a potent inhibitor of ABC transporters, ABCG2/BCRP and ABCB1/Pgp, and is a mild inhibitor of ABCC1/MRP1. In ABCG2-overexpressing HEK293 cells, GDC-0449 increases retention of the fluorescent ABCG2 substrate BODIPY-prazosin and resensitizes these cells to mitoxantrone. In Madin-Darby canine kidney II cells engineered to overexpress Pgp or MRP1, GDC-0449 increases the retention of calcein-AM and resensitizes them to colchicine. GDC-0449 also resensitizes human non-small cell lung carcinoma cells NCI-H460/par and NCI-H460/MX20, which overexpress ABCG2 in response to mitoxantrone, to mitoxantrone, and to topotecan or SN-38. The IC50 values of GDC-0449 for prevention of ABCG2 and Pgp are about 1.4 μM and 3.0 μM, respectively. [2] GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGROV-1 NYToeHpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEeyOFgh|ryP NIfLNpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
HCE-T NWKzcohzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LS[GlEPTB;MT6zNlI1PyEQvF2= NY\OfJd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
D-542MG NWf5eHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LHeGlEPTB;MT64Olc{PyEQvF2= NGexfZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
23132-87 NUD4NXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTRwNECxOFch|ryP MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
HDLM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRThwMES3OlYh|ryP NIf5eIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
ACN M4nKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV35[Gx3UUN3ME24MlUxOTB7IN88US=> M{K2T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HuO-3N1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL5d4tuUUN3ME25MlYxOTB6IN88US=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
BHT-101 NWDwfmN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PkSGlEPTB;MUGuN|gh|ryP M1;1XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
KYSE-150 M3\hZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLPeVBKSzVyPUGxMlU5PDFizszN MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
MC-IXC NITPeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rIbmlEPTB;MUKuNlI6OiEQvF2= M1rnVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
D-423MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF{Lke2OVch|ryP MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
NY MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfqTWM2OD1zND64PVA{KM7:TR?= M37vZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HOS Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG3[HZKSzVyPUG1MlY4OTlizszN NYDKUHFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
NB7 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\lc257UUN3ME2xOU45QTFizszN Ml;QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
DMS-273 NIjrcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHMT2ZzUUN3ME2xOk43PzF|IN88US=> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
MDA-MB-361 MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf1R|ZKSzVyPUG3MlI4OTFizszN MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
DU-145 NIXUUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyySGRKSzVyPUG4MlMzKM7:TR?= NU[xTZg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
NCI-H82 MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\1TWM2OD1zOT64N|g3KM7:TR?= NVLWUlB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
NCI-SNU-1 NUS1b3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfqXYJKSzVyPUKwMlAyQTZizszN NWjycHo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
GCT MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzzVpFKSzVyPUKwMlg5OjRizszN MoHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
C2BBe1 NYHYS21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT6TWM2OD1{MT6xNFU5KM7:TR?= M3m2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
LB2241-RCC NVn6VYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnPTWM2OD1{MT64OFQyKM7:TR?= NYfGOVRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
COLO-829 NUDlTmZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJ{LkG4O|Eh|ryP MkfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
EW-11 NVXuZXZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M372fmlEPTB;MkKuPFAzOiEQvF2= NHXoNHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
NCI-H526 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[zXGlEPTB;MkOuOFcyPyEQvF2= NEOxTpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
SF295 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTEVXlKSzVyPUK0MlAzPTJizszN MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
D-566MG Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XCZ2lEPTB;MkWuNlk1OyEQvF2= NWHuNnRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
8505C MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[wXodiUUN3ME2yOU43OzNzIN88US=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
HT-29 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D1V2lEPTB;Mk[uNFQ{OSEQvF2= M1nJflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
NBsusSR Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPFTWM2OD1{Nj64NFA3KM7:TR?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
BV-173 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3WTWM2OD1{OD6zNVgzKM7:TR?= NVHN[2FGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
CTB-1 NHvQeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HVZmlEPTB;M{CuNVA{OSEQvF2= NGnyO3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
JAR NWrs[XJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN{LkWzO|Eh|ryP NE\GcHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
CAMA-1 M4C4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;VTWM2OD1|Mz60OlE2KM7:TR?= M3;2N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
CAL-51 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW4TWM2OD1|ND63NVc3KM7:TR?= MonkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
A172 MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\USoJKSzVyPUO3MlQ6OjFizszN NHTvZVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
QIMR-WIL NHPBPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTN6LkC3NFgh|ryP MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
AsPC-1 NFLHPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXNXIQ{UUN3ME2zPE41PjVzIN88US=> NIO1XXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
MKN7 NXLM[Wt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHEN|dCUUN3ME2zPU4xODd7IN88US=> NGT4RmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
ONS-76 NIfYTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTR|LkOwOVch|ryP M3P6dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
RS4-11 NE\qWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYGzTWNTUUN3ME20OE4xPzV{IN88US=> MnXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NOS-1 NX\COJlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3ZXpppUUN3ME20OE43ODNzIN88US=> MkTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
A101D M1[2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCzZXFRUUN3ME20OE45ODJ|IN88US=> NGDmNWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
HCC1806 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqzc|ZxUUN3ME20Ok4yOTR6IN88US=> NX7xSZFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
CAL-27 NYHIOpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\OTWM2OD12Nz63NlQ3KM7:TR?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
BT-549 NUDvfVJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PXZ2lEPTB;NEiuOVMyPSEQvF2= NYXhTGJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
LCLC-97TM1 M2S1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnKTWM2OD12OT6yOFE{KM7:TR?= MnHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
A4-Fuk NEOwZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUixeJJ2UUN3ME20PU45PDlizszN MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
OVCAR-4 MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrkZphKSzVyPUWwMlA3ODFizszN MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
HD-MY-Z Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTVyLke3OlQh|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
NCI-H292 MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPKOolKSzVyPUWwMlg4PThizszN MmGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
Sk-ChA-1  NFLuUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\v[lAvOjYkgKO1NEDPxE1? NWfqfYYyPzJiaB?= Mm\STWM2OD15ND61OOKyOi53ON88US=> NIDjXGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0NlQ5Oid-MkW3OFI1QDJ:L3G+
Mz-ChA-1 NGG1ZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfJelgxNjJ34pETOVAh|ryP MXq3NkBp MmDJTWM2OD13ND65O:KyOy52Nd88US=> MkLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEK0PFIoRjJ3N{SyOFgzRC:jPh?=
Smo-WT M4i2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXsVlZuUUN3MNMgc4YhOTUEoH7N NEDKeIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5NVExPCd-MkSyPVEyODR:L3G+
Smo-D473H  NXfVbndoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPxTWM2OMLib3[gO{4yyqEQvF2= NGe2OlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5NVExPCd-MkSyPVEyODR:L3G+
K562 MWTGeY5kfGmxbjDBd5NigQ>? MknLNVAh|ryP MnrHO|IhcA>? Mk\qdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDHcIkyyqB? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzOUiyOEc,OjN|MUm4NlQ9N2F-
T315I BCR-ABL BaF3 NHj6T5FHfW6ldHnvckBCe3OjeR?= NV7leZdwOTBizszN NIDtRYQ4OiCq NF3KWnZz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGdtcTIEoB?= NYfUdGZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVk5OjRpPkKzN|E6QDJ2PD;hQi=>
TF-1 BCR-ABL NYnSNYZmTnWwY4Tpc44hSXO|YYm= NIXROVYyOCEQvF2= MXW3NkBp NX3weotuemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[kBIdGlzwrC= M3fkN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{G5PFI1Lz5{M{OxPVgzPDxxYU6=
Shh-Light 2 MVrGeY5kfGmxbjDhd5NigQ>? NH;4[G8zKGSjeYO= NH\6[3FCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IGPtc{BqdiCvb4Xz[UBUcGhvTHnnbJQhOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNpcC2rbnT1Z4VlKEeuaUGtdoVxd3K2ZYKgZYN1cX[rdImgZYZ1\XJiMjDkZZl{KGK7IHT1ZYwudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJI1mfGixZDygTWM2OCB;IECuNFAyPSEQvF2u NUHGVVBwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
NIH/3T3 NUnUfHRHTnWwY4Tpc44h[XO|YYm= NUjQXXF7UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgUmlJNzOWMzDj[YxteyCkeTDHcIku\HWjbD3seYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7LDDJR|UxKD1iMD6wNFI{KM7:TT6= NXXLVGhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFAxOTJpPkK3NVgxODF{PD;hQi=>
NIH/3T3 Light2 NGjIOnlHfW6ldHnvckBie3OjeR?= NI[5TWFKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiTHnnbJQzKGOnbHzzJIJ6KEeuaT3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjByMkOg{txONg>? NX\0blE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PFgzPzhpPkK4Olg5Ojd6PD;hQi=>
Light2 NGnKTHJHfW6ldHnvckBie3OjeR?= NFewNWY1QCCqcoO= NGG1Z45KdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIFzp[4h1OiClZXzsd{Bi\nSncjC0PEBpenNiYomgS4xqNWy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFAzPDZizszNMi=> NV7RPHgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N|k4OTRpPkK5O|M6PzF2PD;hQi=>
HEPM MXjGeY5kfGmxbjDhd5NigQ>? NF3obYtKdmirYnn0bY9vKG:oIGPITEBqdiCqdX3hckBJTVCPIHPlcIx{KGK7IFfsbU1tfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnOTEA:KDBwMECyPEDPxE1w MkX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5MU[yPVYoRjF7N{G2Nlk3RC:jPh?=
Shh Light2 NI\JNolHfW6ldHnvckBie3OjeR?= NIfPUpVKdmirYnn0bY9vKG:oIGPITEBqdiCvb4Xz[UBUcGhiTHnnbJQzKGOnbHzzJIJ6KEeOST3y[ZNxd26|aY\lJIZqemWobImgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMEOg{txONg>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTNyOUC4NEc,OTl|MEmwPFA9N2F-
HEPM NGPyU4hHfW6ldHnvckBie3OjeR?= MnHxTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC|aXfuZYxqdmdiaX6gbJVu[W5iSFXQUUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5icnXj[ZB1d3JvbXXkbYF1\WRiR3zpNUBuWk6DIHX4dJJme3Orb36gZpkhemWyb4L0[ZIh\2WwZTDhd5NigSxiSV7IJF0hOC5yMEOg{txONg>? M1nlbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEe1O|QyLz5{MEi3OVc1OTxxYU6=
C3H10T1/2 M{jVeGZ2dmO2aX;uJIF{e2G7 NX;yeJZqOjBiaILz M4XqT2lvcGmkaYTpc44hd2ZiU33vJIlvKG2xdYPlJGM{UDFyVEGvNkBk\WyuczD1d4lv\yCqdX3hckBz\WOxbXLpcoFvfCCVSFigZZN{\XO|ZXSgZZMh\W[oZXP0JI9vKFOPTz;TTGghfHKjboPp[Y51KHS{YX7zZ5JqeHSrb37hcEBi[3SrdnH0bY9vKGGodHXyJFIxKGi{czDifUBIdGlvbIXjbYZmemG|ZTDy[ZBwenSncjDhd5NigSxiSVO1NEA:KDBwMEC1JO69VS5? NH;HeVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFQ{Pid-MkS5NFA1OzZ:L3G+
NIH/3T3 NHXlRoJHfW6ldHnvckBie3OjeR?= MYKyOEBpenN? NXLlbWI4UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDOTWgwO1R|IHPlcIx{KG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBIdGlvZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwOUDPxE1w MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW5NUc,Ojd6MUC1PVE9N2F-
NIH3T3 NYDqepZKTnWwY4Tpc44h[XO|YYm= NFm0XWw1QCCqcoO= NY\tWJdEUW6qaXLpeIlwdiCxZjDzcY8udWWmaXH0[YQhcGWmZ3Xoc4che2mpbnHsbY5oKHCjdHj3ZZkhcW5ibX;1d4UhVkmKM2SzJINmdGy|IHX4dJJme3OrbnegS3JGNUy3YzDy[ZBwenSncjDn[Y5mKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhW0GJLXnu[JVk\WRiR2LFMWx2[yC{ZYDvdpRmeiCjY4Tpeol1gSCjZoTldkA1QCCqcoOgZpkhdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yME[g{txONg>? MmrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OUm0PFMoRjJ7NEm5OFg{RC:jPh?=
Shh-light2 MmDESpVv[3Srb36gZZN{[Xl? M{PrSmlvcGmkaYTpc44hd2ZiU33vMY1m\GmjdHXkJGhpKHOrZ37hcIlv\yCrbjDoeY1idiCVaHitcIlocHR{IHPlcIx{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODB5IN88UU4> NUDYU4ZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2PTFpPkKyNlY5PTVzPD;hQi=>
HEK293 NXXwdFRuTnWwY4Tpc44h[XO|YYm= M1jxb|IhcHK| MUTEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NWyjYnXscIVlKGO7Y3zvdIFucW6nIH\yc40hcHWvYX6gV41wKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweHluIFnDOVAhRSByLkCwO{DPxE1w MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEW1NUc,OjJ{Nki1OVE9N2F-
NIH3T3 NH\4[ZBHfW6ldHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGinZHflbI9oKHKnY3XweI9zKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSEPUN{Bk\WyuczD0doFve2[nY4Tl[EB4cXSqIFfsbU1z\XCxcoTldkBo\W6nIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEC3NVch|ryPLh?= NVTqNZpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NlM4PjVpPkK0PVI{PzZ3PD;hQi=>
NIH/3T3 M2[1bmZ2dmO2aX;uJIF{e2G7 M1;QU|Q5KGi{cx?= MVTJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIGPvcolkKGinZHflbI9oNWmwZIXj[YQhT2yrIHz1Z4ln\XKjc3WgZYN1cX[rdImgZYZ1\XJiNEigbJJ{KGK7IFT1ZYwudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wNFcyPyEQvF2u NY\LNFZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyOFk1QTRpPkOwNlQ6PDl2PD;hQi=>
NIH3T3 Mmf1SpVv[3Srb36gZZN{[Xl? NXnudY1EPDhiaILz NX;qUmNGUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyuaX7nJIlvKG2xdYPlJG5KUDOWMzDj[YxteyC|dHHicJkhfHKjboPm[YN1\WRid3n0bEBIdGlvbIXjbYZmemG|ZTDjc45{fHK3Y4SgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwO|Ih|ryPLh?= NF\1do89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkiyO|E{Pid-Mk[4NlcyOzZ:L3G+
NIH3T3 Ml\CSpVv[3Srb36gZZN{[Xl? NFLZSlg1QCCqcoO= MUHJcohq[mm2aX;uJI9nKFOxbnnjMYlv\HWlZXSgbIVl\2Wqb3egd4lodmGubHnu[{BqdiCvb4Xz[UBPUUh|VEOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KEeuaT3seYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7LDDJR|UxKD1iMD6wNFczKM7:TT6= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh{MEW1OEc,OjZ6MkC1OVQ9N2F-
NIH3T3 MmX4SpVv[3Srb36gZZN{[Xl? M1P2cVQ5KGi{cx?= NUjjNVA{UW6qaXLpeIlwdiCxZjDTTGghe2mpbnHsbY5oKHCjdHj3ZZkhcW5ibX;1d4UhVkmKM2SzJINmdGy|IH3lZZN2emWmIHHmeIVzKDR6IHjyd{BjgSCJbHmtcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygTWM2OCB;IECuNFA4OiEQvF2u MoPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{[zPVYoRjJ2MUe2N|k3RC:jPh?=
NIH/3T3 NW\HTIM2TnWwY4Tpc44h[XO|YYm= M4Dk[VQ5KGi{cx?= NYjFRm1UUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDOTWgwO1R|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBIdGlvbIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4xODd{IN88UU4> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NkKwN{c,OjR2OE[yNFM9N2F-
NIH/3T3 NI\vVWNHfW6ldHnvckBie3OjeR?= M{TaUmlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM|NVOyClZXzsd{BjgSCJbHmxMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEC3NkDPxE1w NWnaZppIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFU4ODRpPkK0OFA2PzB2PD;hQi=>
NIH/3T3 MnLCSpVv[3Srb36gZZN{[Xl? M4HwNGlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM|NVOyClZXzsd{Bk[XK{eXnu[{B{fGGkbImgeJJidnOoZXP0[YQhT2yrLYLldI9zfGW{IHPvcpN1enWldDDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGG|c3H5MEBKSzVyIE2gNE4xODd{IN88UU4> NWizXpd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2OFIyODFpPkK4OlQzOTBzPD;hQi=>
C3H10T1/2 M1nDV2Z2dmO2aX;uJIF{e2G7 MVu2JIhzew>? M33WdWlvcGmkaYTpc44hd2ZiU1HHMYlv\HWlZXSg[Iln\mW{ZX70bYF1cW:wIH;mJI1wfXOnIH3ld4Vv[2i7bXHsJJBtfXKrcH;0[Y51KEN|SEGwWFEwOiClZXzsd{B1dyCjbHvhcIlv\SCyaH;zdIhifGG|ZTDwc5NqfGm4ZTDv[ZNmd2KuYYP0d{Bi\nSncjC2JIhzeyxiSVO1NEA:KDBwMEGxJO69VS5? NX3OUJVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2PTFpPkKyNlY5PTVzPD;hQi=>
HCC827 MUnGeY5kfGmxbjDhd5NigQ>? MYXEbZNxdGGlZX3lcpQhd2ZiW{PIYU1kgWOub4DhcYlv\SCocn;tJHNOVyCYNEC0UUBufXSjboSgbY4h\2WoaYTpcoljKHKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3mgQUAxNjBzMkKg{txONg>? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd6N{G1Okc,Ojh5OEexOVY9N2F-
C3H10T1/2 M{POdmZ2dmO2aX;uJIF{e2G7 Mn\pTY5pcWKrdHnvckBw\iCVSFigbY4hdW:3c3WgR|NJOTCWMT:yJINmdGy|IHL5JGdtcS2udXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlAyOyEQvF2u MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdzNkK5Okc,OTl5MU[yPVY9N2F-
S12 MmnGSpVv[3Srb36gZZN{[Xl? MmLuTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC|aXfuZYxqdmdiaX6gcY92e2ViU{GyJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC{ZXPldJRwei2vZXTpZZRm\CCJbHmxJI1TVkFiZYjwdoV{e2mxbjDifUBz\XCxcoTldkBo\W6nIHHzd4F6NCCLTligQUAxNjBzMzFOwG0v NYD0cWRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O|U4PDFpPkKwPFc2PzRzPD;hQi=>
TM3 NWPpOZRuTnWwY4Tpc44h[XO|YYm= NGrYTZk1QCCqcoO= MkDWTY5pcWKrdHnvckBw\iCKaDDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDUUVMh[2WubIOgZZN{\XO|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhT2yrMTDn[Y5mKGW6cILld5Nqd25iYX\0[ZIhPDhiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuNFE{KM7:TT6= M13l[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUe2NlE2Lz5{Nkm3OlIyPTxxYU6=
NIH/3T3 NVLCbYJuTnWwY4Tpc44h[XO|YYm= NVXifo1kUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDOTWgwO1R|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIGPtc{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gS4xqKG2UTlGg[ZhxemW|c3nvckBjgSCUVD3QR3IhdWW2aH;kMEBKSzVyIE2gNE4xOTR2IN88UU4> NV;5[otRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
S12 NVfSdnp5TnWwY4Tpc44h[XO|YYm= NXnvfmxkPDhiaILz MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHNJUCCyYYToe4F6KGmwIH3veZNmKFNzMjDj[YxteyCjc4Pld5Nm\CCjczDHUGkudWWmaXH0[YQhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIFnfGW{IES4JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjBzNTFOwG0v NWrxdm8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0N|g2OjdpPkKxOFM5PTJ5PD;hQi=>
NIH/3T3 NXHQenh1TnWwY4Tpc44h[XO|YYm= NFG1UXRKdmirYnn0bY9vKG:oIGPNU{BqdiCvb4Xz[UBPUUhxM2SzJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiU1HHMYlv\HWlZXSgbIVl\2Wqb3etcYVlcWG2ZXSgcJVucW6nc3PlcoNmKHOrZ37hcIlv\yCkeTDHVmUudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wNVYh|ryPLh?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUWwNEc,OjZzMUm1NFA9N2F-
U2OS NFnSc2lHfW6ldHnvckBie3OjeR?= MnHINkBpenN? MYXEbZNxdGGlZX3lcpQhd2ZiW{PIYYN6[2yxcHHtbY5mKG[{b32ge4lt\CC2eYDlJHNudyCneIDy[ZN{\WRiaX6gWVJQWyClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNaTC9JFAvODF4MjFOwG0v MoKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ|ME[zOVIzRC:jPh?=
NIH3T3 MYnGeY5kfGmxbjDhd5NigQ>? M{KxSlMxKGi{cx?= MmnsTY5pcWKrdHnvckBw\iCVbX:gdoVk\XC2b4KgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hVkmKM2SzJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiU33vJIFod26rc4SgV2FINWmwZIXj[YQhT1KHIHHjeIl3[XSrb36gZYZ1\XJiM{CgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODJ|IN88UU4> MnSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mk[4NFcoRjJ2N{K2PFA4RC:jPh?=
medulloblastoma cell MkjZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MX[zOkBpenN? NUDOeGI5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBRfGOqKz:tJIFv\CCyNUOtM{0hdW:3c3WgcYVlfWyub3LsZZN1d22jIHPlcIx{KGGodHXyJFM3KGi{czDifUBDemS3IHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTBiPTCwMlA{ODRizszNMi=> NHzFfYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4PFI4QCd-Mki2PFgzPzh:L3G+
Shh Light2 MYLGeY5kfGmxbjDhd5NigQ>? M2OxPGFvfGGpb37pd5Qh[WO2aY\peJkh[XRic33vc5Rp\W6nZDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDTbIghVGmpaISyJINmdGy|IHPvMYV5eHKnc4PpcochT2yrLXTldIVv\GWwdDDy[ZBwenSncjDn[Y5mKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUGhic3nncoFtcW6pIHL5JIR2[WxibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4xOzNizszNMi=> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
Light2 MWfGeY5kfGmxbjDhd5NigQ>? NVHrTIFsUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDMbYdpfDJiY3XscJMhcW5iU3joJINwdmSrdHnvcoVlKG2nZHn1cUBjgSCJbHmtcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yM{mg{txONg>? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh5M{OwN{c,Ojh6N{OzNFM9N2F-
Shh Light2 MXTGeY5kfGmxbjDhd5NigQ>? NX7Ld29UUW6qaXLpeIlwdiCxZjDTcY8udWWmaXH0[YQhUGhic3nncoFtdGmwZzDwZZRpf2G7IHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiYomgS4xqNWy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFM6OiEQvF2u NHXLR3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ezOlA3Oyd-Mke3N|YxPjN:L3G+
ASZ001 MYDGeY5kfGmxbjDhd5NigQ>? M2q4PVQ5KGi{cx?= MnfNTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC|aXfuZYxqdmdiaX6gcY92e2ViQWPaNFAyKGOnbHzzJIF{e2W|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaUGgcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDR6IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjB2IN88UU4> NYDYVoNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OTZpPkK0PVAxPzF4PD;hQi=>
NIH/3T3 NYnkbVJsTnWwY4Tpc44h[XO|YYm= M3XmVlQ5KGi{cx?= MlXLRY51[WexbnnzeEBi[3Srdnn0fUBifCCVbX:gdoVk\XC2b4KgbY4hdW:3c3WgUmlJNzOWMzDj[YxteyCqYYLic5JqdmdiR2LFMWx2[yCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFODRz3pcoR2[2WmIFjoJJNq\26jbHnu[{Bx[XSqd3H5JJBz\WmwY4XiZZRm\CC5aYToJINmdGy|IH\vcIxwf2WmIHL5JHNCTyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wOFYh|ryPLh?= NH3QSGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1O|I4PSd-Mkm4OVczPzV:L3G+
Light2 NIjuc4FHfW6ldHnvckBie3OjeR?= M3LRVlMxKGi{cx?= NHfCelZKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIFzp[4h1OiClZXzsd{BqdiCVaHigZ49v\Gm2aX;u[YQhdWWmaYXtJIFnfGW{IEOwJIhzeyCkeTDHcIkuWmWwaXzsZUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkC1JO69VS5? M3vVRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEm5NlU4Lz5|MEC5PVI2PzxxYU6=
C3H10T1/2 MXXGeY5kfGmxbjDhd5NigQ>? M{PtOFYh\GG7cx?= NYTaR3R7UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeT3t[YRq[XSnZDDkbYZn\XKnboTpZZRqd25ib3[gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJHNCTy2rbnT1Z4VlKEGOUDDhZ5Rqfmm2eTDh[pRmeiB4IHThfZMh[nliY3jlcYltfW2rbnXzZ4Vv[2VvYnHz[YQh[XO|YYmsJGlEPTBiPTCwMlA2KM7:TT6= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7OUK1O{c,OzByOUmyOVc9N2F-
DaOY MVzGeY5kfGmxbjDhd5NigQ>? NFT5eGc1QCCqcoO= MmKxTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC|aXfuZYxqdmdiaX6gbJVu[W5iRHHPXUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBIdGlzIH3SUmEh\XiycnXzd4lwdiCjZoTldkA1QCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nzMEBKSzVyIE2gNE4xQDZizszNMi=> NFixdG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
C3H10T1/2 NEjlNXFHfW6ldHnvckBie3OjeR?= MWqxJIhz NHH5fFJKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIFOzTFExXDFxMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4heHW{bX;ydIhidWmwZT3pcoR2[2WmIHnuZ5Jm[XOnIHnuJIFtc2GuaX7lJJBpd3OyaHH0ZZNmKGyndnXsJJV{cW6pIFPEVE1{fGG{IHHzJJN2[nO2cnH0[UBxemW2cnXheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IID1do1wenCqYX3pcoUh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOUBl[XluIFnDOVAhRSByLkG0JO69VS5? MmTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NEe5N|koRjJ6OUS3PVM6RC:jPh?=
M210B4 M3zwN2Z2dmO2aX;uJIF{e2G7 M3rDXFI1KGi{cx?= MYTJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCPMkGwRlQh[2WubIOgZZN{\XO|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhWHSlaDDtVm5CKGW6cILld5Nqd25iYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBidmGueYPpd{whUUN3MDC9JFAvOTRizszNMi=> NG\0Sm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
M210B4 MmDhSpVv[3Srb36gZZN{[Xl? NX;GcJlJOjRiaILz NELJeJZKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBud3W|ZTDNNlExSjRiY3XscJMh[XO|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiR3zpNUBuWk6DIHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyxiSVO1NEA:KDBwMjFOwG0v NGfncYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
Shh Light2 NXHERVV[TnWwY4Tpc44h[XO|YYm= MojPNUBpeg>? MoPGTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC|aXfuZYxqdmdiaX6gcY92e2ViU3joJGxq\2i2MjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4heHW{bX;ydIhidWmwZT3pcoR2[2WmIFfsbUBu\WSrYYTl[EB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgdJJmfHKnYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCydYLtc5JxcGGvaX7lJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IES4JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjl6IN88UU4> M4DlS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUS3PVM6Lz5{OEm0O|k{QTxxYU6=
NIH/3T3 MVnGeY5kfGmxbjDhd5NigQ>? M1L3WWlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM|NVOyClZXzsd{Bp[XKkb4LpcochW22xIFS0O|dJKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gS4xqKG2UTlGg[ZhxemW|c3nvckBjgSCUVD3QR3IhdWW2aH;kMEBKSzVyIE2gNU4yQTZizszNMi=> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW5NUc,Ojd6MUC1PVE9N2F-
S12 NH7nTI9HfW6ldHnvckBie3OjeR?= M3fze|Q5KGi{cx?= NEe4R45KdmirYnn0bY9vKG:oIHj1cYFvKFOKSDDwZZRpf2G7IHnuJI1wfXOnIGOxNkBk\WyuczDhd5Nme3OnZDDhd{BIVElvbXXkbYF1\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XliaX6gdJJme2WwY3Wgc4YhOC53IH3nM41NKGi3bXHuJIFteGijLUGtZYNq\CCpbInjc5Bzd3SnaX6sJGlEPTBiPTCxMlc2KM7:TT6= NYq0T5JIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0N|g2OjdpPkKxOFM5PTJ5PD;hQi=>
Calu6 MkHtSpVv[3Srb36gZZN{[Xl? NXzOdHZpPCCqcoO= MXrQcIF{dWFiY3;uZ4VvfHKjdHnvckBqdiCqdX3hckBE[Wy3NjDj[YxteyC6ZX7v[5Ji\nSnZDDpckBvfWSnIH3veZNmKGG2IEe1JI1oN2upLDDwc{BjcWRibXXhd5Vz\WRiYX\0[ZIhPCCqcoOgdI9{fCCoaX\0bEBld3OnLDDDdEA:KDJ|IN88UU4> M2PZb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G2Nlk3Lz5zOUexOlI6PjxxYU6=
Calu-6 NWm4fFJoTnWwY4Tpc44h[XO|YYm= NGHsWlJRdGG|bXGgZ49v[2WwdILheIlwdiCrbjDDZYx2NTZiY3XscJMhgGWwb3fyZYZ1\WRiboXk[UBud3W|ZTDQT{9RTCCvb3TlcEBifCB5NTDt[{9s\yxicH:gZollKG[xcjC1JIRigXNibXXhd5Vz\WRiNDDodpMheG:|dDDsZZN1KGSxc3WgdoVt[XSrdnWgeI8hfW62cnXheIVlKGOxboTyc4wtKEOyIE2gNlMh|ryPLh?= NVH2S4sxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O|U4PDFpPkKwPFc2PzRzPD;hQi=>
T47D MnfPR5l1d3SxeHnjbZR6KGG|c3H5 NFnBbXc4OiCqcoO= NYntdIlnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPDFwM{Sg{txONg>? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyN{SyPUc,OjlzMEe0Nlk9N2F-
LS180 M4TRfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NHrrT4w4OiCqcoO= NXjWcW16SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMV|E5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmVvQjDhd5NigSxiSVO1NEA:KDR3IN88UU4> NWPPfpo5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwPVkzPTdpPkOwNFk6OjV5PD;hQi=>
LS174T NI\3fWpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NXfLdGdPPzJiaILz MmrDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOU{G3OHQh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTBiPTC0OU45OSEQvF2u MmjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6MkC1OVQoRjJ4OEKwOVU1RC:jPh?=
BxPC3 M2W0O2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NHj6bGc4OiCqcoO= M1TDZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQojQR|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTBiPTC0O{46PSEQvF2u NY\JfWU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NlA2PTRpPkK2PFIxPTV2PD;hQi=>
medulloblastoma cell MW\BcpRqfHWvb4KgZZN{[Xl? NWHncZhrSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdW:3c3WgcYVlfWyub3LsZZN1d22jIHPlcIx{KHinbn;ndoFnfGWmIHnuJHB1[2hiKz:tJI1wfXOnIHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHS3bX;yJJZwdHWvZTDheEAyOi53IH3nM4toNCCybzDibYQv MnHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5MU[yPVYoRjF7N{G2Nlk3RC:jPh?=
S12 M1j3eGZ2dmO2aX;uJIF{e2G7 NHfVNVQ1QCCqcoO= NEjGenhKdmirYnn0bY9vKG:oIHj1cYFvKFOKSDDwZZRpf2G7IHnuJI1wfXOnIGOxNkBk\WyuczDhd5Nme3OnZDDhd{BIVElvbXXkbYF1\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XliaX6gdJJme2WwY3Wgc4YhOSCvZz;tUEBpfW2jbjDhcJBp[S1zLXHjbYQh\2y7Y3;wdo91\WmwLh?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR|OEWyO{c,OjF2M{i1Nlc9N2F-
Shh Light2 MoDuSpVv[3Srb36gZZN{[Xl? MV6wMlEhfU1? NEPmXnA{PiCqcoO= NXzzZZVFUW6qaXLpeIlwdiCxZjDTcY8udWWmaXH0[YQhUGhic3nncoFtdGmwZzDwZZRpf2G7IHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiR3zpNU1uWk6DIHX4dJJme3Orb36gZZQhOC5zIIXNJI1m[XO3cnXkJIFnfGW{IEO2JIhzeyCkeTDSWE1yWEOUIHHuZYx6e2m|Lh?= NXPoNZRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3N|YxPjNpPkK3O|M3ODZ|PD;hQi=>
SW1353 NUnvZoV3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MlO2NVAhfU1? M4Prc|Q5KGi{cx?= M{PuOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2exN|U{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGG2IEGwJJVOKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkv MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
DaOY MlTnRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1TGSFExKHWP NYLaZnZ6PDhiaILz MoPzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGYV;ZJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyIIXNJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmu MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
A549 Mn75RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NX7qcoJQOTBidV2= MXu0PEBpenN? M33hO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBifCBzMDD1UUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5Mi=> M{jPfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEmxOFU6Lz5{NES5NVQ2QTxxYU6=
HCT116 M4HqSmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MUixNEB2VQ>? NF\HZnU1QCCqcoO= NUfLVHZPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYYSgNVAhfU1iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigS5? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
NIH/3T3 M33TRWZ2dmO2aX;uJIF{e2G7 MoTUNVAhfU1? MluzTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC|aXfuZYxqdmdiaX6gcY92e2ViTlnIM|NVOyClZXzsd{Bie3Onc4Pl[EBieyCmb4fuJJJm\3WuYYTpc44hd2ZibWDUR2gyKG2UTlGg[ZhxemW|c3nvckBifCBzMDD1UU4> NHKxVIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5NVQ2QSd-MkS0PVE1PTl:L3G+
MSC M4XBRWZ2dmO2aX;uJIF{e2G7 NW\WPYQ4OjBidH:gPFAhfU1? M4rHXmlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIF3TR{Bk\WyuczDhd5Nme3OnZDDhd{Bld3ewIILl[5Vt[XSrb36gc4Yh[WytYXzpcoUheGixc4DoZZRie2ViYYSgNlAhfG9iOECgeW0v MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
SK-N-MC Mn[zdWhVWyCjc4PhfS=> NH[xeJZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsd{4> MoTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 M1\RdJFJXFNiYYPzZZk> M1f0T5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJMv M{fMSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NIH3T3-Luc MnS5SpVv[3Srb36gZZN{[Xl? MUCxJJVO NFjLRoI1QCCqcoO= MUPJcohq[mm2aX;uJI9nKHOvbz3t[YRq[XSnZDDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDOTWg{XDNvTIXjJINmdGy|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGdtcSCvUl7BJIV5eHKnc4Ppc44h[XRiMTD1UUBi\nSncjC0PEBpenNiYomgdoVidC22aX3lJHBEWiCjbnHsfZNqey5? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR7OUS4N{c,Ojl2OUm0PFM9N2F-
C3H10T1/2 NUX5SmZqTnWwY4Tpc44h[XO|YYm= M4HhfVI1KGi{cx?= M4XS[WlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XlvbXXkbYF1\WRiR1zJNUBuWk6DIHX4dJJme3Orb36gbY4hdW:3c3WgR|NJOTCWMT:yJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMhcW5icILld4Vv[2Vib3[gLFFTNDOjUjy0V{w4[VJrLUfhMY1mfGi7bD2xMUgpWilvNj3t[ZRpgWyqZYD0ZY4uOi27bDnvZ5RicHmmcn:tNWgucW6mZX6tOE16dCB|LXj5[JJwgHmkZX76c4F1\S5? MmjWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5M{C5PFQoRjJ2N{OwPVg1RC:jPh?=
C3H10T1/2 M3X6XWZ2dmO2aX;uJIF{e2G7 M{T4TFI1KGi{cx?= MmXtTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC|aXfuZYxqdmdicHH0bJdigS2vZXTpZZRm\CCJTFmxJI1TVkFiZYjwdoV{e2mxbjDpckBud3W|ZTDDN2gyOFRzL{KgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjDWSFMv NGTGXFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEezNFk5PCd-MkS3N|A6QDR:L3G+
NIH/3T3 MlPvSpVv[3Srb36gZZN{[Xl? NGS4eJYyODBibl2= M2Djc|M3KGi{cx?= NHn3VoVKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiY3XscJMh[XO|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiU3joMYlv\HWlZXSgS4xqOSCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJIF1KDFyMDDuUUBi\nSncjCzOkBpenNiYomgVnQueVCFUjDhcoFtgXOrcz6= NF;MRYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi3N|MxOyd-Mki4O|M{ODN:L3G+
C3H10T1/2 NYL6epRnTnWwY4Tpc44h[XO|YYm= NFH3[JoyODBibl2= M{Lu[FM3KGi{cx?= NXjVRYIzUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDDN2gyOFRzL{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gV4hpNWmwZIXj[YQhT2yrMTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KGG2IEGwNEBvVSCjZoTldkA{PiCqcoOgZpkhWlRvcWDDVkBidmGueYPpd{4> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh5M{OwN{c,Ojh6N{OzNFM9N2F-
NIH/3T3 NWP6XGxDTnWwY4Tpc44h[XO|YYm= MoHCNVAxKG6P MUezOkBpenN? NXvoWVd{UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDOTWgwO1R|IHPlcIx{KGG|c3Xzd4VlKGG|IHTve45z\We3bHH0bY9vKG:oIGPobE1qdmS3Y3XkJJB1[2hzIH3SUmEh\XiycnXzd4lwdiCuZY\lcJMh[XRiMUCwJI5OKGGodHXyJFM3KGi{czDifUBTXC2zUFPSJIFv[Wy7c3nzMi=> Mn;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN|A{RC:jPh?=
C3H10T1/2 MWfGeY5kfGmxbjDhd5NigQ>? M{TVTlExOCCwTR?= MkLrN|YhcHK| NIW5VG9KdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIFOzTFExXDFxMjDj[YxteyCjc4Pld5Nm\CCjczDkc5dvemWpdXzheIlwdiCxZjDTbIgucW6mdXPl[EBxfGOqMTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KGG2IEGwNEBvVSCjZoTldkA{PiCqcoOgZpkhWlRvcWDDVkBidmGueYPpd{4> MnqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN|A{RC:jPh?=
medulloblastoma cell MmP5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NWTRNXRjfXBidH:gN|AhfU1? NViyU3hvPzJiaILz MnfyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCSdHPoL{8uKHB3Mz2vMUBu\WS3bHzvZoxie3SxbXGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygdJJwdGmoZYLheIlwdiC3cDD0c{A{OCC3TTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7Lh?= MoTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN|A{RC:jPh?=
medulloblastoma cell M4rUXGFxd3C2b4Ppd{Bie3OjeR?= NVzGOIlWUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBud3W|ZTDQeINpMy9vIIC1N{0wNSCvZXT1cIxw[myjc4TvcYEh[2WubIOgbY1xdGGwdHXkJIlvKGG2aIntbYMhdnWmZTDtc5V{\SCjdDCxNk42KG2pL3vnMEBqeCCkaXSg[o9zKDF3IHPvcpNm[3W2aY\lJIRigXNiYomgWHVPTUxiYYPzZZkv NUTHZ2pSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4O|M{ODNpPkK4PFc{OzB|PD;hQi=>
NIH/3T3 NGDQVGRHfW6ldHnvckBie3OjeR?= NUDvPVdHUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDlfJBz\XO|ZXSgbY4hdW:3c3WgUmlJNzOWMzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGinZHflbI9oNWmwZIXj[YQhT2yrLUKgZYNkfW23bHH0bY9vKGG2IITpdEBw\iCycnntZZJ6KGOrbHnhJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiY3;u[o9k[WxibXnjdo9{[2:yaXOgZY5idHm|aYOu NV[0TXlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
NIH/3T3 M37adWZ2dmO2aX;uJIF{e2G7 NWjiXpU4UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDOTWgwO1R|IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhcGWmZ3Xoc4cucW6mdXPl[EBUdW9vRVfGVEBkcWyrYYL5JJRz[W6|bH;jZZRqd25iYomgSGFRUSC|dHHpcolv\yCkYYPl[EBkd26ob3PhcEBucWO{b4Pjc5Bq[yCjbnHsfZNqey5? Mk[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PVEoRjJ5OEGwOVkyRC:jPh?=
medulloblastoma cell NU\mbpVKSW62aT30eY1weiCjc4PhfS=> NGPqWI5CdnSrLYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdW:3c3WgVJRkcCtxLTDwOVMuNy1ibXXkeYxtd2KuYYP0c41iKGOnbHzzJIlueGyjboTl[EBqdiCjdHj5cYlkKG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgNlAhdWdxa3esJJBwKGGmbXnubZN1\XKnZDD0e4lk\SCmYXnsfUB3cWFiZ3H2ZYdmKG2nYYP1doVlKGW4ZYL5JI91cGW{IHThfUBlfXKrbnegZ49ueG:3bnSg[I9{cW6pLh?= NVnXeHZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N|k4OTRpPkK5O|M6PzF2PD;hQi=>
C3H10T1/2 MXrGeY5kfGmxbjDhd5NigQ>? NVHyRo9JPC5zIITvJFExODBibl2= NWSxcGFrSWyub4P0[ZJq[yCrbnjpZol1cW:wIH;mJHNudyCrbjDtc5V{\SCFM1ixNHQyNzJiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxfXKvb4LwbIFucW6nLXnu[JVk\WRiR3zpNUB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgZZQhPC5zIITvJFExODBibl2gZpkheVCFcjDhcoFtgXOrcz6= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5NEW0NUc,OjNyN{S1OFE9N2F-
C3H10T1/2 NILPOGhHfW6ldHnvckBie3OjeR?= NGDse|E1NjFidH:gNVAxOCCwTR?= MknUR49ueGW2aYTpeoUhcW6qaXLpeIlwdiCxZjDTcY8hcW5ibX;1d4UhSzOKMUDUNU8zKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gV2FINWmwZIXj[YQhT2yrMTD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYYSgOE4yKHSxIEGwNFAhdk1iYomgdXBEWiCjbnHsfZNqey5? M33Qc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEe0OVQyLz5{M{C3OFU1OTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fas / DR4 / DR5 / Cleaved PARP / Bcl-2 / Cleaved caspase-3 / PDGFRα; 

PubMed: 22087285     


Pancreatic CSCs were treated with GDC-0449 (0, 1, 5 and 10 µM) for 48 h. The expression of Fas, DR4/TRAIL-R1, DR5/TRAIL-R2, PARP cleavage, Bcl-2, and Caspase-3 by the Western blot analysis. β-Actin was used as a loading control.

p-GSK3β / GSK3β / p-Akt / Akt / Gli1; 

PubMed: 27143997     


Cells were pretreated with or without 30 μM GDC-0449 for 2 h before TMT treatment. After incubation with 3.75 μM TMT for another 24 h, the expression levels of proteins were determined through Western blot analysis.

Gli1 / SOX2 / OCT4; 

PubMed: 26418365     


The activation of Hedgehog pathways and CSC markers were tested by immunoblotting analysis in Hs578T and BT549 cells. β‐Actin was used as a loading control.

p53 / Cyclin D1 / p21; 

PubMed: 28195165     


GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies.

Bcl-2 / Bax; 

PubMed: 28195165     


GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies.

22087285 27143997 26418365 28195165
Immunofluorescence
Gli1 / Gli2; 

PubMed: 22087285     


GDC-0449 inhibits expression of Gli1 and Gli2 in human pancreatic CSCs. The cells were seeded on fibronectin-coated coverslips and treated with GDC-0449 (10 µM) for 48 h. Subsequently, cells were fixed with 4% paraformaldehyde, blocked in 10% normal goat serum and stained with Gli1 and Gli2 primary antibodies (1∶100) for 16 h at 4°C and washed with PBS. Afterwards, cells were incubated with fluorescently labeled secondary antibody (1∶200) along with DAPI (1 mg/ml) for 1 h at room temperature and cells were mounted and visualized under a fluorescent microscope. For better visuality, the color of DAPI was changed from blue to red.

22087285
Growth inhibition assay
Cell viability; 

PubMed: 29042665     


GDC-0449 improves the anti-proliferation activity in NIH-3T3 cells but not in BxPC-3, Panc-1, MIAPaca-2 and SW1990 cells when cultured alone. The cytotoxicities of GDC-0449, Dox or Dox with GDC-0449 (5 μM or 10 μM) were measured by performing a 48-h MTT assay in BxPC-3 (A), Panc-1 (B), MIAPaca-2 (C), SW1990 (D) and NIH-3T3 (E) cells. Apoptosis rate was detected by flow cytometry (Annexin V staining) analysis after treatment with Dox (200 nM) with or without GDC-0449 for 24 h (F). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01.

29042665
In vivo GDC-0449 has been used to treat medulloblastoma in animal models. [2] GDC-0449 prevents the growth of primary pancreatic xenografts without non-specifically inhibiting pancreatic cell proliferation. Oral dosing of GDC-0449 causes tumor regressions in the Ptch(+/-) allograft model of medulloblastoma at doses ≥25 mg/kg and tumor growth inhibition at doses up to 92 mg/kg dosed twice daily in two ligand-dependent colorectal cancer models, D5123, and 1040830. Analysis of Hh pathway activity and PK/PD modeling reveals that GDC-0449 inhibits Gli1 with a similar IC50 in both the medulloblastoma and D5123 models (0.165 μM and 0.267 μM, respectively). Pathway modulation is linked to efficacy using an integrated PK/PD model revealing a steep relationship where > 50% of the activity of GDC-0449 is associated with >80% repression of the Hh pathway. [4]

Protocol

Cell Research:[2]
- Collapse
  • Cell lines: MDCKII cells
  • Concentrations: 20 μM
  • Incubation Time: 2 hours
  • Method: MDCKII cells are seeded into 24-well plates at a density of 3 × 105 cells per well and are allowed to attach. Medium is then changed to that containing different drugs (50 μM VP, 50 μM indomethacin, or 20 μM GDC-0449 in DMSO or DMSO alone as control, and nonfluorescent calcein-AM is added to a final concentration of 1.0 μM and incubated at 37 °C for 2 hours. Cells are then washed twice with Ca2+, Mg2+-containing Hank's balanced salt solution buffer and lysed by shaking in 0.01% Triton X-100 in PBS buffer for 1 hour at room temperature or overnight at 4 °C. The lysate is then transferred into 96-well plates, and the fluorescence signal caused by the cell-derived calcein is quantified spectrophotometrically with a SpectraMax M5 Multi-Detection Readerusing an excitation wavelength of 495 nm and an emission wavelength of 515 nm. All manipulations are performed in the dark. All readings are expressed as mean ?SEM normalized to the control.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Ptch(+/-) allograft model, D5123 and 1040830
  • Dosages: ~ 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.38 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
For best results, use promptly after mixing.
12.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.3
Formula

C19H14Cl2N2O3S

CAS No. 879085-55-9
Storage powder
in solvent
Synonyms N/A
Smiles CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03610022 Recruiting Drug: Treatment with vismodegib Metastatic Basal Cell Carcinoma|Locally Advanced Basal Cell Carcinoma University Hospital Bordeaux September 3 2018 Phase 4
NCT03035188 Active not recruiting Drug: Vismodegib Basal Cell Carcinoma SRH Wald-Klinikum Gera GmbH January 2017 Phase 2
NCT02781389 Active not recruiting -- Basal Cell Carcinoma University Hospital Essen|OnkoDataMed GmbH April 29 2016 --
NCT02593760 Completed Other: Placebo|Drug: Ruxolitinib|Drug: Vismodegib Myelofibrosis Hoffmann-La Roche January 25 2016 Phase 1
NCT02648048 Completed Drug: Pirfenidone|Drug: Vismodegib Idiopathic Pulmonary Fibrosis Hoffmann-La Roche January 15 2016 Phase 1
NCT02366312 Completed Drug: vismodegib Keratocystic Odontogenic Tumor NYU College of Dentistry|Genentech Inc. October 27 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Vismodegib|Vismodegib ic50|Vismodegib price|Vismodegib cost|Vismodegib solubility dmso|Vismodegib purchase|Vismodegib manufacturer|Vismodegib research buy|Vismodegib order|Vismodegib mouse|Vismodegib chemical structure|Vismodegib mw|Vismodegib molecular weight|Vismodegib datasheet|Vismodegib supplier|Vismodegib in vitro|Vismodegib cell line|Vismodegib concentration|Vismodegib nmr|Vismodegib in vivo|Vismodegib clinical trial|Vismodegib inhibitor|Vismodegib Stem Cells & Wnt inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID